New and emerging lipid-lowering therapy

James M. Backes, Daniel E. Hilleman

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Statins remain the drugs of choice in patients at risk of or with atherosclerotic cardiovascular disease (ASCVD). Statins have limitations that drive the development of investigational agents to manage dyslipidemias and/or reduce ASCVD risk. There are a few small-molecule drugs that have the potential to mitigate ASCVD risk either alone or in combination with statins. Most lipid-modifying drugs in clinical development are biologic agents that target specific enzymes or genetic-based protein synthesis. Limitations of the biologic agents include complex mechanisms of action and manufacturing processes with indications in select patients with genetic dyslipidemia or who have failed traditional therapies. The ultimate clinical utility of the new and investigational agents will become established over the next several years.

Original languageEnglish (US)
Pages (from-to)1407-1420
Number of pages14
JournalFuture Cardiology
Issue number8
StatePublished - Nov 2021

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'New and emerging lipid-lowering therapy'. Together they form a unique fingerprint.

Cite this